Home / Library / Topic Index / HIV Continuum of Care / Step 5: Effective Drug Treatment of HIV

Step 5: Effective Drug Treatment of HIV

See also Antiretroviral Therapy, Adherence, and Initiating Treatment

Active Resources: 39

Self-Study Materials

Antiretroviral Guidelines

Online Training

Pocket Guides

Clinical Reference Tools

Webinar Recordings

Toolkits

Image Library

Primary Care Guidelines

Charts, Tables & Posters

Slide Sets

Videos

Patient Information

Articles & Bibliographies

Coinfection Guidelines (Hep, TB, STIs)

Manuals

Fact Sheets

Articles: 6

  • Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)

    April 11, 2018

    Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...

  • Ibalizumab Approved for Persons with Multidrug Resistant HIV

    April 11, 2018

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Ibalizumab (TNX-355), an entry inhibitor, has been approved by the FDA for use in persons with an extensive ARV treatment history and multidrug resistant HIV who are on a failing ARV regimen. Ibalizumab (trade name: Trogarzo) is a monoclonal antibody that binds the CD4 receptor and blocks HIV...

  • Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

    August 31, 2017

    Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

    The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...

  • CROI 2017: Failure of Dolutegravir Monotherapy

    April 17, 2017

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...

  • Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

    April 12, 2016

    Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...

  • Switching from TDF/FTC to TAF/FTC

    March 18, 2016

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...
Day Title
12/3
2018 Biomedical HIV Prevention Summit (The Summit) (California)
Monday, December 3, 2018 (All day) (Open Event)
National Minority AIDS Council
Event type: Conferences & Events
Day Title
3/16
American Pharmacists Association Annual Meeting and Exposition 2018 (Tennessee)
Friday, March 16, 2018 (All day) to Monday, March 19, 2018 (All day) (Open Event)
Event type: Conferences & Events
3/4
CROI 2018: Boston (Online, National, Massachusetts)
Sunday, March 4, 2018 (All day) to Wednesday, March 7, 2018 (All day) (Open Event)
International Antiviral Society-USA
Event type: Conferences & Events
10/23
National Day of Action to End Violence Against Women with HIV (National)
Monday, October 23, 2017 (All day) (Open Event)
Event type: Awareness Days